Sulpirid Hexal

Sulpirid Hexal may be available in the countries listed below.

Ingredient matches for Sulpirid Hexal

Sulpiride

Sulpiride is reported as an ingredient of Sulpirid Hexal in the following countries:

• Germany

International Drug Name Search

United Home Ketoconazole

United Home Ketoconazole may be available in the countries listed below.

Ingredient matches for United Home Ketoconazole

Ketoconazole

Ketoconazole is reported as an ingredient of United Home Ketoconazole in the following countries:

• Philippines

International Drug Name Search

Klaricid I.V.

Klaricid I.V. may be available in the countries listed below.

Ingredient matches for Klaricid I.V.

Clarithromycin

Clarithromycin lactobionate (a derivative of Clarithromycin) is reported as an ingredient of Klaricid I.V. in the following countries:

• Mexico

International Drug Name Search

Kaliumchlorid Bichsel

Kaliumchlorid Bichsel may be available in the countries listed below.

Ingredient matches for Kaliumchlorid Bichsel

Potassium Chloride

Potassium Chloride is reported as an ingredient of Kaliumchlorid Bichsel in the following countries:

• Switzerland

International Drug Name Search

Piroxicam-Mepha

Piroxicam-Mepha may be available in the countries listed below.

Ingredient matches for Piroxicam-Mepha

Piroxicam

Piroxicam is reported as an ingredient of Piroxicam-Mepha in the following countries:

• Switzerland

International Drug Name Search

Combistress

Combistress may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Combistress

Acepromazine

Acepromazine maleate (a derivative of Acepromazine) is reported as an ingredient of Combistress in the following countries:

• Belgium

International Drug Name Search

Bicarbonate de Sodium Baxter

Bicarbonate de Sodium Baxter may be available in the countries listed below.

Ingredient matches for Bicarbonate de Sodium Baxter

Sodium Bicarbonate

Sodium Bicarbonate is reported as an ingredient of Bicarbonate de Sodium Baxter in the following countries:

• France


• Luxembourg

International Drug Name Search

Buspirone Hydrochloride

Ingredient matches for Buspirone Hydrochloride

Buspirone

Buspirone Hydrochloride (BANM, USAN) is known as Buspirone in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Isovue-370

See also: Generic Isovue-200, Generic Isovue-250, Generic Isovue-300

Isovue-370 is a brand name of iopamidol, approved by the FDA in the following formulation(s):

ISOVUE-370 (iopamidol - injectable; injection)

• 
  Manufacturer: BRACCO
  
  Approval date: December 31, 1985
  
  Strength(s): 76% ^[RLD][AP]


• 
  Manufacturer: BRACCO
  
  Approval date: October 12, 1994
  
  Strength(s): 76% ^[RLD][AP]

Has a generic version of Isovue-370 been approved?

Yes. The following products are equivalent to Isovue-370:

IOPAMIDOL-370 (iopamidol injectable; injection)

• 
  Manufacturer: APP PHARMS
  
  Approval date: April 2, 1997
  
  Strength(s): 76% ^[AP]

SCANLUX-370 (iopamidol injectable; injection)

• 
  Manufacturer: SANOCHEMIA CORP USA
  
  Approval date: June 18, 2010
  
  Strength(s): 76% ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Isovue-370. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Isovue-370.

See also...

• Isovue-370 Consumer Information (Cerner Multum)
• Iopamidol Consumer Information (Cerner Multum)

Ebastina Winthrop

Ebastina Winthrop may be available in the countries listed below.

Ingredient matches for Ebastina Winthrop

Ebastine

Ebastine is reported as an ingredient of Ebastina Winthrop in the following countries:

• Spain

International Drug Name Search

Geodon

Geodon is a brand name of ziprasidone, approved by the FDA in the following formulation(s):

GEODON (ziprasidone hydrochloride - capsule; oral)

• 
  Manufacturer: PFIZER
  
  Approval date: February 5, 2001
  
  Strength(s): EQ 20MG BASE ^[RLD], EQ 40MG BASE, EQ 60MG BASE, EQ 80MG BASE
  

GEODON (ziprasidone hydrochloride - suspension; oral)

• 
  Manufacturer: PFIZER INC
  
  Approval date: March 29, 2006
  
  Strength(s): EQ 10MG BASE/ML ^[RLD]

GEODON (ziprasidone mesylate - injectable; intramuscular)

• 
  Manufacturer: PFIZER
  
  Approval date: June 21, 2002
  
  Strength(s): EQ 20MG BASE/ML ^[RLD]

Has a generic version of Geodon been approved?

No. There is currently no therapeutically equivalent version of Geodon available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Geodon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Aryl piperazinyl-(C.sub.2 or C.sub.4) alkylene heterocyclic compounds having neuroleptic activity
  Patent 4,831,031
  Issued: May 16, 1989
  Inventor(s): Lowe, III; John A. & Nagel; Arthur A.
  Assignee(s): Pfizer Inc.
  Arylpiperazinyl-ethyl(or butyl)-heterocyclic compounds and their pharmaceutically acceptable acid addition salts are neuroleptic agents. They are useful in the treatment of psychotic disorders.
  
  Patent expiration dates:
  
  
  • March 2, 2012
    
    ✓ 
    Patent use: TREATMENT OF NEUROLEPTIC DISEASES
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dih ydro-2H-indol-2-one-hydrochloride
  Patent 5,312,925
  Issued: May 17, 1994
  Inventor(s): Allen; Douglas J. M. & Busch; Frank R. & DiRoma; Sabeto A. & Godek; Dennis M.
  Assignee(s): Pfizer Inc.
  The monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2H-indole-2-one hydrochloride has advantageous stability for formulation as a neuroleptic agent.
  
  Patent expiration dates:
  
  
  • September 1, 2012
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 1, 2012
    
    ✓ 
    Patent use: TREATMENT OF NEUROLEPTIC DISEASES
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
  Patent 6,110,918
  Issued: August 29, 2000
  Inventor(s): Busch; Frank R. & Rose; Carol A.
  Assignee(s): Pfizer Inc
  Mesylate Trihydrate Salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one (=Ziprasidone), Its Preparation and Its Use as Dopamine D2 Antagonist The invention relates to the mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one ("ziprasidone mesylate trihydrate"), to pharmaceutical compositions containing ziprasidone mesylate trihydrate, and to methods of administering ziprasidone mesylate trihydrate to treat psychotic diseases.
  
  Patent expiration dates:
  
  
  • March 26, 2017
    
  
  



• 
  Ziprasidone formulations
  Patent 6,150,366
  Issued: November 21, 2000
  Inventor(s): Arenson; Daniel R. & Busch; Frank Robert & Hausberger; Angela G. & Rasadi; Bijan
  Assignee(s): Pfizer Inc.
  Compositions comprising crystalline ziprasidone free base or crystalline ziprasidone hydrochloride particles having a mean particle size less than 85 .mu.m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to treat psychoses such as schizophrenia.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Drug product
  
  
  
  • May 27, 2019
    
    ✓ 
    Patent use: TREATENT OF PSYCHOSIS
    ✓ 
    Drug product
  
  



• 
  Inclusion complexes of aryl-heterocyclic salts
  Patent 6,232,304
  Issued: May 15, 2001
  Inventor(s): Kim; Yesook & Johnson; Kevin C. & Shanker; Ravi M.
  Assignee(s): Pfizer Inc.
  Compositions of matter comprising a pharmaceutically acceptable salt of an aryl-heterocyclic compound, such as ziprasidone, in a cyclodextrin. Preferred cyclodextrins are SBECD and HPBCD. The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution. The salt/cyclodextrin inclusion complex preferably provides an amount of ziprasidone of at least 2.5 mgA/ml when the complex is dissolved in water at 40% w/v. A variety of ziprasidone salts are preferred, including the mesylate, esylate, besylate, tartrate, napsylate, and tosylate.
  
  Patent expiration dates:
  
  
  • April 1, 2017
    
  
  



• 
  Method of treating psychiatric conditions
  Patent 6,245,766
  Issued: June 12, 2001
  Inventor(s): Watsky; Eric J.
  Assignee(s): Pfizer Inc
  A method for treating a psychiatic condition or disorder selected from anxiety disorders such as panic disorder, posttraumatic stress disorder and phobias, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder and mood disorders associated with psychotic disorders such as acute mania or depression associated with bipolar disorder, schizophrenia, behavioral manifestations of mental retardation, conduct disorder or autistic disorder, dementias such as dementias of the Alzheimer's type, and dyskinesias such as drug induced and neurodegeneration based dyskinesias in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.
  
  Patent expiration dates:
  
  
  • December 18, 2018
    
    ✓ 
    Patent use: TREATMENT OF BIPOLAR DISORDER
  
  



• 
  Inclusion complexes of aryl-heterocyclic salts
  Patent 6,399,777
  Issued: June 4, 2002
  Inventor(s): Yesook; Kim & Kevin C.; Johnson & Ravi M.; Shanker
  Assignee(s): Pfizer Inc.
  The esylate, mesylate, and tartrate salts of ziprasidone exhibit excellent solubilities in cyclodextrins.
  
  Patent expiration dates:
  
  
  • April 1, 2017
    
  
  



• 
  Ziprasidone suspension
  Patent 7,175,855
  Issued: February 13, 2007
  Inventor(s): Arenson; Daniel R. & Qi; Hong
  Assignee(s): Pfizer Inc.
  Compositions comprising ziprasidone free base or a difficult to wet pharmaceutically acceptable ziprasidone acid addition salt, a polysorbate, and colloidal silicon dioxide form good aqueous suspensions having a useful shelf life and are easily re-suspended if setting occurs.
  
  Patent expiration dates:
  
  
  • May 18, 2020
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 20, 2012 - MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
  
  

See also...

• Geodon Consumer Information (Drugs.com)
• Geodon Consumer Information (Wolters Kluwer)
• Geodon Capsules Consumer Information (Wolters Kluwer)
• Geodon Consumer Information (Cerner Multum)
• Geodon Advanced Consumer Information (Micromedex)
• Geodon Intramuscular Advanced Consumer Information (Micromedex)
• Geodon AHFS DI Monographs (ASHP)
• Ziprasidone Consumer Information (Wolters Kluwer)
• Ziprasidone Capsules Consumer Information (Wolters Kluwer)
• Ziprasidone Consumer Information (Cerner Multum)
• Ziprasidone Advanced Consumer Information (Micromedex)
• Ziprasidone Intramuscular Advanced Consumer Information (Micromedex)
• Ziprasidone AHFS DI Monographs (ASHP)

Néfazodone

Néfazodone may be available in the countries listed below.

Ingredient matches for Néfazodone

Nefazodone

Néfazodone (DCF) is known as Nefazodone in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Piriteze

Piriteze may be available in the countries listed below.

UK matches:

• Piriteze Allergy Syrup (SPC)
• Piriteze Allergy Tablets (GSL) (SPC)
• Piriteze Allergy Tablets (P) (SPC)

Ingredient matches for Piriteze

Cetirizine

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Piriteze in the following countries:

• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Introvit-K3

Introvit-K3 may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Introvit-K3

Menadione

Menadione sodium sulfonate (a derivative of Menadione) is reported as an ingredient of Introvit-K3 in the following countries:

• Netherlands

International Drug Name Search

Sinutab NS

Sinutab NS may be available in the countries listed below.

Ingredient matches for Sinutab NS

Tetryzoline

Tetryzoline hydrochloride (a derivative of Tetryzoline) is reported as an ingredient of Sinutab NS in the following countries:

• Philippines

International Drug Name Search

Silimarit

Silimarit may be available in the countries listed below.

Ingredient matches for Silimarit

Silibinin

Silibinin is reported as an ingredient of Silimarit in the following countries:

• Germany

International Drug Name Search

Alfaferone

Alfaferone may be available in the countries listed below.

Ingredient matches for Alfaferone

Interferon alfa

Interferon alfa is reported as an ingredient of Alfaferone in the following countries:

• Czech Republic


• Italy


• Poland


• Slovakia

International Drug Name Search